Cellular Biomedicine Group has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Cellular Biomedicine Group, 2018, MAR 5, 2018, View Source [SID1234524374]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 5, 2018 MyBiotics Pharma Ltd., a microbiome therapeutics company, reported that it has entered into a second option agreement with Ferring Holding Ltd. for the validation of MyBiotics’ microbiome-based therapeutics in the field of women’s health (Press release, MyBiotics, MAR 5, 2018, View Source [SID1234577656]). This agreement follows the first agreement between the two parties signed in June 2017, for the validation of MyBiotics’ technology in the treatment of a non-disclosed gastroenterology condition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MyBiotics has developed breakthrough and robust production and fermentation techniques for growing a highly stable and diverse bacterial community that can be delivered to the gut efficiently and can reliably restore microbiome equilibrium. The technology is highly potent and suitable for patients with medical indications related to the microbiome or for those who use antibiotics. Preclinical tests have shown that MyBiotics’ products deliver enhanced durability in various gastrointestinal and manufacturing conditions, enable targeted release in different gastrointestinal locations and exhibit robust colonization in the gut, with a stable bacterial population observed for 14 days following treatment.

"Within a few months we have entered into two collaborations with Ferring Holding, which is a true vote of confidence in the potential of our therapeutic approach", stated David Daboush, CEO of MyBiotics Pharma. "Our technology enables us to generate concentrated and effective bacterial raw material that can be introduced into the gastrointestinal tract and restore ecological equilibrium to the gut microbiota. Combining our innovative technology with the extensive drug development and marketing expertise of the Ferring Group has the potential to lead to novel treatments in the fields of gastroenterology and women’s health, offering patients long term relief without significant risks."

"This agreement is further evidence of Ferring’s commitment to seek out novel treatments for important medical conditions. Ferring is very active in the areas of gastroenterology and women’s health, and this partnership with MyBiotics is another indication of our commitment to discover and develop innovative microbiome-based treatments," said Dov Kanner, Director of Ferring Holding. "It is clear by now that the microbiome is of profound importance to a wide variety of pathologies, ranging from digestive disorders through obesity, immune disorders, women’s health and more. Microbiome-based therapies are gaining increasing interest for a variety of microbiome-related indications, and we believe that MyBiotics’ technology will enable the development of such therapies, potentially offering treatment to millions of people around the globe."

Currently available probiotic drugs and dietary supplements have limited clinical impact due to the low survival rates of the delivered bacteria in the gastrointestinal tract. This significantly reduces the ability of probiotic bacteria to impact the microbial diversity of the gut, thus failing to create a healthier community of bacteria.

On March 5,2018 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, Chief Executive Officer, will present at the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California the 30th Annual Roth Conference on March 12th, 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation via the "Investors & Media" section of our website, www.arqule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation

On March 5, 2018 VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, reported that Shawn Singh, Chief Executive Officer, will present at Oppenheimer’s 28th Annual Healthcare Conference in New York City at 8:00 a.m. Eastern Time on Wednesday, March 21, 2018 (Press release, VistaGen Therapeutics, MAR 5, 2018, View Source [SID1234524401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information about the conference, or to schedule a one-on-one meeting with VistaGen’s management, please contact your Oppenheimer representative directly, or visit the conference website: View Source

On March 5, 2018 Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) reported that, at three upcoming investor conferences in March, President, Chief Executive Officer and co-founder, Steven J. Mento, Ph.D., and Conatus Executive Vice President, Chief Operating Officer and Chief Financial Officer, Keith W. Marshall, Ph.D., M.B.A., will focus on the company’s expected announcements of clinical trial results (Press release, Conatus Pharmaceuticals, MAR 5, 2018, View Source [SID1234524367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We intend to use the upcoming conferences to provide context for our four planned data readouts, the first being the announcement of top-line results from our POLT-HCV-SVR trial in the second quarter," said Dr. Mento. "This randomized, placebo-controlled Phase 2b trial is evaluating two years of treatment with emricasan, our first-in-class pan-caspase inhibitor, in post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy."

"In collaboration with Novartis, we expect to announce top-line results from four ongoing Phase 2b clinical trials in 2018 and 2019, including the POLT-HCV-SVR trial, two trials in nonalcoholic steatohepatitis (NASH) cirrhosis, and one in NASH fibrosis," said Dr. Marshall. "We are also advancing with our independent pipeline expansion activities and expect to provide further updates later this year. We believe our current financial resources, together with the anticipated reimbursements for 50% of the costs for the four ongoing clinical trials, without including any potential milestone payments under the Novartis collaboration, are sufficient to maintain operations through top-line results from all four Phase 2b clinical trials by the end of 2019, as well as to fund initial pipeline expansion activities."

At the Roth Capital Partners 30th Annual Conference (March 11-14 in Laguna Niguel, CA), Dr. Mento will participate in two panel discussions on NASH cirrhosis on Monday, March 12, as part of the integrated Spring NASH Bash. Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 1:30 p.m. ET on Monday, March 12.

At the H.C. Wainwright 2nd Annual NASH Investor Conference (March 19 in New York), Dr. Marshall will present a NASH-focused presentation beginning at 3:40 p.m.

At the Oppenheimer Healthcare Conference (March 20-21 in New York), Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 10:20 a.m. ET on Wednesday, March 21. An audio webcast and copy of the Oppenheimer conference presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.